Pluri

PLUR

Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.

Pluri has been a target of short sellers for a while. The current short interest of 0.21% is roughly at the average of the last 12 months (0.17%).